SA001 + rebamipide

SA001 + rebamipide is a fixed-dose oral combination of two related agents. SA001 is a prodrug of rebamipide developed by Samjin Pharmaceuticals to enhance systemic exposure and bioavailability compared to conventional rebamipide. Upon administration, SA001 is rapidly converted in vivo to active rebamipide. Rebamipide itself is an amino acid derivative of 2-(1H)-quinolinone with established gastroprotective and mucosal healing properties. It acts by stimulating prostaglandin synthesis (notably COX-2), scavenging free radicals, enhancing mucin production, suppressing neutrophil activity and cytokine production (including TNF-α), and increasing blood flow via nitric oxide synthase activation. The combination aims to leverage both improved pharmacokinetics from the prodrug (SA001) and direct therapeutic effects from both forms for indications such as dry eye disease (DED) with autoimmune features as well as gastrointestinal mucosal protection[2][1][3]. Clinical trials have demonstrated that oral administration of SA001 results in higher plasma concentrations of active rebamipide than conventional formulations[2].